A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Table 3 Gene expession associated with patient outcomes

	Control set	P-value*	Bev qPCR Set	P-value*
ORR
*ALDH6A1 + TFF2 + MCM5*
All low	4/11 (36.4%)	0.747	6/7 (85.7%)	0.007
Other	27/61 (44.3%)		12/42 (28.6%)
Odds ratio for response
*ALDH6A1 + TFF2 + MCM5*
All low vs. any other	0.72	0.6273	15.00	0.0168
Hazard ratio for progression
*KLF12 + TFF2*
Other vs. (KLF12 high + TFF2 low)	1.29	0.39	2.92	0.03
*ALDH6A1 + TFF2*
Other vs. All low	1.76	0.0404	0.89	0.7406

*Critical point for the significance of p-values is a = 0.05/(N of comparisons) = 0.05/27 = 0.001852 (Bonferroni correction).

ISSN: 1471-2407